Company & Sponsor Intelligence

Cephalon

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials7

Recruiting0

Completed6

Countries1

Therapeutic footprint

adhddepressionpain_neuropathyparkinsonsschizophrenia

Indexed studies

NCT00343733Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
pain_neuropathy · United StatesPHASE3

NCT00343811Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment
adhd · United StatesPHASE3

NCT00040404Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
parkinsons · United StatesPHASE2, PHASE3

NCT01072630Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
depression · United StatesPHASE3

NCT00315276Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
adhd · United StatesPHASE2

NCT00813488Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain
pain_neuropathy · United StatesPHASE3

NCT00772005Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia
schizophrenia · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →